Objective: To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods: In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results: Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively. Conclusion: Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence. © Colégio Brasileiro de Radiologia e Diagnóstico por Imagem.
CITATION STYLE
Franca, C. A. da S., Vieira, S. L., Carvalho, A. C. P., Bernabe, A. J. S., & Penna, A. B. R. C. (2014). A relação entre PSA nadir de dois anos e recidiva bioquímica no tratamento do câncer de próstata com braquiterapia de semente de iodo-125. Radiologia Brasileira, 47(2), 89–93. https://doi.org/10.1590/S0100-39842014000200010
Mendeley helps you to discover research relevant for your work.